CytRx Corporation Highlights Patent Issued for New Aldoxorubicin Formulation

LOS ANGELES, June 26, 2019 /PRNewswire/ --CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that it has been issued a patent from the U.S. Patent and Trademark Office (USPTO) covering the formulation, storage, delivery and administration of aldoxorubicin at room temperature.